Abstract
The past ten years have seen a rapid expansion in the field of cardiovascular pharmacology. New indications for old agents have appeared and new powerful drugs have been introduced, including entirely new classes of compounds. The availability of so many agents has considerably expanded the risk of life-threatening adverse reactions due to overdosage or to inappropriate drug associations. The liability to encounter severe side effects is often enhanced in patients with underlying cardiovascular diseases, which may change the usual drug action either by inducing modifications of the drug pharmacokinetic or by altering the receptor sensitivity. In most cases these kind of reactions are predictable on the ground of the knowledge of both the drug mechanism of action and the functional alterations induced by the disease. However entirely unexpected adverse reactions may also occur in cases in which unrecognized alterations exist, whose pathophysiology has not been fully elucidated. Recent demonstrations that some physiopatho-logical influences, as well as prolonged drug treatment, can modulate the number of adrenergic receptors in the cardiovascular system has offered a clue to a better understanding of at least some episodes of altered responsiveness to cardiovascular drugs, previously considered of unknown origin. The possibility of obtaining some indications of the adrenoceptor status in man, by the assessment of the receptor density in circulating blood cells, seems to represent a promising diagnostic approach to the problem of disease induced adrenergic regulation and its possible consequences in terms of altered drug responsiveness.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aarons RD, Nies AS, Gal J, Hegstrand LR, Molinoff PB (1980) Elevation of beta adrenergic receptor density in human lymphocytes after propranolol administration. J Clin Invest 65: 949–957
Akera T, Brown BS (1982) Cardiovascular toxicology of cardiotonic drugs and chemicals. In: Van Stee EW (ed) Cardiovascular toxicology. Raven Press, New York, p 109
Alexander CS (1972) Cobalt beer cardiomyopathy — A clinical and pathologic study on twenty-eight cases. Am J Med 53: 395–417
Andreasen F, Mikkelsen E (1977) Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol 12: 15–22
Balasubramanian V, McNamara DB, Singh JN, Dhalla NS (1973) Biochemical basis of heart function. Reduction in the Na+-K+-stimulated ATPase activity in failing rat heart to hypoxia. Can J Physiol Pharmacol 51: 504–510
Baughman RA, Lin ET, Williams RL, Benet LZ (1979) Prazosin disposition in patients with congestive heart failure and in healthy controls. Clin Pharmacol Ther 25: 213
Baum GL, Dick MM, Blum A, Kaupe A, Carballo J (1959) Factors involved in digitalis sensitivity in chronic pulmonary insufficiency. Am Heart J 57: 460–462
Beller GA, Conroy J, Smith TW (1976) Ischemia induced alterations in myocardial (Na+-K+)-AT-Pase and cardiac glycoside binding. J Clin Invest 57: 341–350
Benowitz NL, Meister W (1976) Pharmacokinetics in patients with cardiac failure. Clin Pharmacokinet 1: 389–405
Boudoulas M, Lewis RP, Kates RE, Dalamangas G (1977) Hypersensitivity to adrenergic stimulation after propranolol withdrawal in normal subjects. Ann Intern Med 87: 433–436
Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and beta adrenergic-receptor density in failing human hearts. N Engl J Med 307: 205–211
Chew CYC, Hecht HS, Collett JT, McAllister RG, Singh BN (1981) Influence of severity of ventricular function on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol 47: 917–922
Christensen NJ (1972) Increased levels of plasma noradrenaline in hypothyroidism. J Clin Endocrinol Metab 35: 359–363
Cluff LE (1966) Adverse reactions to drugs: methods of study. In: Lasagna L (ed) International encyclopedia of pharmacology and therapeutics, sect 6, vol II. Pergamon Press, Oxford London, p 655
Deglin SM, Deglin JM, Chung EK (1977) Drug induced cardiovascular diseases. Drugs 14: 29–40
Doherty JE (1982) The digoxin-quinidine interaction. Annu Rev Med 33: 163–170
Durrer D, Schuillenburg RM, Wellens HJJ (1970) Preexcitation revisited. Am J Cardiol 25: 690–697
Fazzini PF, Marchi F, Pucci P (1973) Q-T lungo, sincope e prenilamina. Giorn It Cardiol 3: 233–239
Ferrier GR, Saunders JM, Mendez C (1973) A cellular mechanism for the generation of ventricular arrhythmias by acetylstrophantidin. Circ Res 33: 508–515
Fleckenstein A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17: 149–166
Gaffney TE, Braunwald E (1963) Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 34: 320–324
Green LH, Smith TW (1977) The use of digitalis in patients with pulmonary disease. Ann Intern Med 87: 459–465
Greenblatt DJ, Koch-Weser J (1974) Adverse reactions to beta adrenergic blocking drugs: A report from the Boston Collaborative Drug Surveillance Program. Drugs 7: 118–129
Hagemeijer F (1978) Verapamil in the management of supraventricular tachyarrhythmias occurring after a recent myocardial infarction. Circulation 57: 751–755
Jackson G, Harrison DC (1980) Adverse effects of beta-adrenergic blocking drugs. In: Bristow MR (ed) Drug-induced heart disease. Elsevier-North Holland, Amsterdam New York Oxford, p 323
Kass RS, Lederer WJ, Tsien RW, Weingart R (1978) Role of calcium ions in transient inward currents and aftercontractions induced by strophantidin in cardiac Purkinje fibers. J Physiol 281: 187–208
Kohlhardt M, Bauer B, Krause H, Fleckenstein A (1973) Selective inhibition of the transmembrane Ca conductivity of mammalian myocardial fibers by Ni, Co and Mn ions. Pflügers Arch 338: 115–123
Morrison J, Killip T (1971) Hypoxemia and digitalis toxicity in patients with chronic lung disease. Circulation 43/44: II 44
Murakami K, Kasama T, Hayashi R, Tsushima M, Nishiomeda Y, Koh H, Nambu S, Ikeda M (1982) Myxoedema coma induced by beta-adrenoceptor-blocking agent. Br Med J 285: 543–544
Opie LH (1980) Metabolic and drug-induced injury to the myocardium. In: Bristow MR (ed) Drug-induced heart disease. Elsevier-North Holland Biomedical Press, Amsterdam New York Oxford, p 81
Reynolds EW, Vander Ark CR (1976) Quinidine syncope and the delayed repolarization syndromes. Mod Concepts Cardiovasc Dis 45: 117–122
Schwartz PJ, Stone HL (1978) Unilateral stellectomy and sudden death. In: Schwartz PJ, Brown AM, Malliani A, Zanchetti A (eds) Neural mechanisms in cardiac arrhythmias. Raven Press, New York, p 107
Schwartz PJ, Periti M, Malliani A (1975) The long Q-T syndrome. Am Heart J 89: 378–390
Sellers DT Jr, Basmore TM, Gallagher JJ (1977) Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation 56: 260–267
Shand DG, Wood AJJ (1978) Editorial: propranolol withdrawal syndrome: why? Circulation 58: 202–203
Singer DH, Ten Eick RE (1981) Chronic dysrhythmias: A new look at old questions. Prog Cardiovasc Dis 24: 91–96
Singer DH, Baumgarten CM, Ten Eick RE (1981) Cellular electrophysiology of ventricular and other dysrhythmias: Studies on diseased and ischemic heart. Prog Cardiovasc Dis 24: 97–156
Singh BN, Roche AHG (1977) Effects of intravenous verapamil on hemodynamics in patients with heart disease. Am Heart J 94: 79–85
Stenson RE, Constantino RT, Harrison DC (1971) Interrelationships of hepatic blood flow, cardiac output and blood levels of lidocaine in man. Circulation 43: 205–211 Stephen SA (1966) Unwanted effects of propranolol. Am J Cardiol 18: 463–468
Stiles GL, Lefkowitz RJ (1981) Thyroid hormone modulation of agonist-beta adrenergic receptor interaction in the rat heart. Life Sci 28: 2529–2536
Thomas JA, Marks BH (1978) Plasma norepinephrine in congestive heart failure. Am J Cardiol 41: 233–243
Ueda CT, Dzindzio BS (1978) Quinidine kinetics in congestive heart failure. Clin Pharmacol Ther 23: 158–164
Velebit V, Podrid P, Lown B, Cohen BM, Graboys TB (1982) Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65: 886–894
Williams RL, Benet LZ (1980) Drug pharmacokinetics in cardiac and hepatic disease. Ann Rev. Pharmacol Toxicol 20: 389–413
Williams LT, Snyderman R, Lefkowitz RJ (1976) Identification of beta adrenergic receptors in human lymphocytes by (3H) alprenolol binding. J Clin Invest 57: 149–155
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag
About this paper
Cite this paper
Ledda, F. (1984). Alterations of Drug Toxicity in Cardiovascular Disease. In: Chambers, P.L., Preziosi, P., Chambers, C.M. (eds) Disease, Metabolism and Reproduction in the Toxic Response to Drugs and Other Chemicals. Archives of Toxicology, vol 7. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-69132-4_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-69132-4_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-12452-8
Online ISBN: 978-3-642-69132-4
eBook Packages: Springer Book Archive